Melanoma research reaches a milestone
21 March 2017
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
Melanoma Institute Australia (MIA) has been collecting samples from melanoma patients since 1999 and now has an incredible resource that is powering melanoma research here and around the globe. Together with patient records, the samples add enormous value to the clinical stories of our patients and drive discovery and translational research that will, in turn, provide answers to the clinical questions plaguing our doctors.
“When a patient first presents to MIA, we don't have the crystal ball to predict what their journey is going to be like,” says Biospecimen Bank Manager, Valerie Jakrot (pictured). “We now know that melanoma is not just one disease, and so we must look at the molecular level to understand the differences between each type.”
Because of the large number of samples collected, MIA and collaborators from around the world have access to a wide variety of different types of melanoma, including some of the rarer forms, growing our understanding of the disease. In addition, a large number of samples are needed to test and confirm hypotheses in research, and so the Biospecimen Bank’s magnitude is invaluable.
By using the samples to identify which genes drive the disease, researchers will gain a better understanding to improve patient outcomes. This is the basis of personalised medicine.
“By finding out which genes are involved in causing a patient’s melanoma, we will be able to better predict the course of the disease and identify which treatment will be most effective for the patient,” says Valerie. “This knowledge will change the management of patients from the very beginning, ensuring the best possible outcome is reached.”
Biospecimen Bank samples have also been used in a number of key research projects, including the Australian Melanoma Genome Project, which is mapping the entire genome of 500 melanomas. Our samples have contributed significantly to The Cancer Genome Atlas (TCGA), a five year study of tumours from over 300 patients around the world. In addition, data has been made available to the International Cancer Genome Consortium (ICGC), which is seeking to understand the genetic causes of 50 different cancer types.
Contributions making a difference
As the largest collection of melanoma blood and tissue samples in the world, the Biospecimen Bank would not have been established without significant resources from MIA. Being a specialised treatment centre, MIA has access to a large number of patients who generously consent to being part of this endeavour. Without the support of our patients, and donors who see the long-term potential of this project, the Biospecimen Bank simply wouldn’t exist.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play